E-mail: robert.kralovics@cemm.oeaw.ac.at
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy
- Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients
- Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Study
- FUNCTIONAL AND GENOME-WIDE ANALYSIS OF ACQUIRED RESISTANCE TO TRAIL/APO2L MEDIATED APOPTOSIS OF HL60 LEUKEMIA CELLS
- Heterogenity of Myeloproliferative Disorders: Genetic Basis, Clonal Complexity, and Implications for Therapy
- HIGH RESOLUTION CYTOGENETIC MAPPING AND WHOLE EXOME SEQUENCING REVEAL A COMPLEX PATTERN OF CHROMOSOME 6P ABERRATIONS IN PATIENTS WITH MYELOID MALIGNANCIES
- Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing
- Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
- Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed Patients with Essential Thrombocythemia: The ANAHYDRET-Study.
- PROGNOSTIC SIGNIFICANCE OF GENETIC ABERRATIONS IN SECONDARY ACUTE MYELOID LEUKEMIA
- Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study
- The Role of JAK2-V617F Oncogenic Mutation in Thrombosis Associated with Myeloproliferative Disorders
- VYHLEDÁVÁNÍ A SLEDOVÁNÍ KLONŮ S MUTACÍ TP53 V CHRONICKÉ FÁZI MYELOPROLIFERATIVNÍCH NEOPLAZIÍ (MPN)
- Whole Exome Sequencing Identifies Novel MPL and JAK2 Mutations in Triple Negative Myeloproliferative Neoplasms
